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866 The Journal of Thoracic and CardioObjective: Myocardial infarction leads to cardiomyocyte loss. The cytokine leuke-
mia inhibitory factor regulates the differentiation and growth of embryonic and adult
heart tissue. This study examined the effects of gene transfer of leukemia inhibitory
factor in infarcted rat hearts.
Methods: Lewis rats underwent ligation of the left anterior descending coronary
artery and direct injection of adenovirus encoding leukemia inhibitory factor (n
 10) or null transgene as control (n  10) into the myocardium bordering the
ischemic area. A sham operation group (n  10) underwent thoracotomy without
ligation. After 6 weeks, the following parameters were evaluated: cardiac
function with a pressure-volume conductance catheter, left ventricular geometry
and architecture by histologic methods; myocardial fibrosis by Masson
trichrome staining, apoptosis by terminal deoxynucleotidal transferase–medi-
ated deoxyuridine triphosphate nick-end labeling assay, and cardiomyocyte size
by immunofluorescence.
Results: Rats with overexpression of leukemia inhibitory factor had more pre-
served myocardium and less fibrosis in both the infarct and its border zone. The
border zone in leukemia inhibitory factor–treated animals contained fewer
apoptotic nuclei (1.6%  0.1% vs 3.3%  0.2%, P  .05) than that in control
animals and demonstrated cardiomyocytes with larger cross-sectional areas (910
 60 m2 vs 480  30 m2, P  .05). Leukemia inhibitory factor–treated
animals had increased left ventricular wall thickness (2.1  0.1 mm vs 1.8  0.1
mm, P  .05) and less dilation of the left ventricular cavity (237  22 L vs
301  16 L, P  .05). They also had improved cardiac function, as measured
by maximum change in pressure over time (3950  360 mm Hg/s vs 2750  230
mm Hg/s, P  .05) and the slopes of the maximum change in pressure over
time– end-diastolic volume relationship (68  5 mm Hg/[s · L] vs 46  6 mm
Hg/[s · L], P  .05) and the preload recruitable stroke work relationship (89
 10 mm Hg vs 44  4 mm Hg, P  .05).
Conclusions: Myocardial gene transfer of leukemia inhibitory factor preserved
cardiac tissue, geometry, and function after myocardial infarction in rats.
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PCongestive heart failure (CHF) affects 5 mil-lion patients in the United States and even-tually occurs in 22% to 46% of patientsafter an acute myocardial infarction (MI).1The cardiac dysfunction in ischemic car-diomyopathy is due in part to loss of myo-
cardium at the time of the initial MI. A subsequent remod-
eling process involving cardiomyocyte apoptosis leads to
progressive left ventricular (LV) dilation, fibrosis, and wall
thinning, culminating in CHF.2-4
The heart has been considered postmitotic and incapable
of self-repair, leading to attempts to regenerate functional
myocardium by transplanting exogenous cells into injured
areas.5,6 However, heart transplant tissue has recently been
found to contain a significant number of cells that had
migrated from the recipient to integrate both as muscle and
vascular cells in the transplanted heart.7,8 Recent studies
have also shown that stem cells both in the heart and
mobilized from the bone marrow contribute to myocardial
repair.9,10 These findings indicate that the heart has some
capability for repair, although the signals regulating this
process are unknown.
Leukemia inhibitory factor (LIF) is an interleukin 6–
related cytokine that regulates the differentiation, growth,
function, and regeneration of both embryonic and adult
tissues.11-13 In the heart, LIF induces hypertrophy, blocks
apoptosis, and affects the differentiation, proliferation, and
maintenance of cardiomyocytes.14-17 After acute myocar-
dial injury, LIF downregulates myofibroblast differentia-
tion, collagen deposition, and matrix metalloproteinase ac-
tivity in cardiac fibroblasts.12 LIF also increases expression
of vascular endothelial growth factor and manganese super-
oxide dismutase.18,19 Overall, LIF’s actions appear to pre-
serve cardiomyocyte integrity and function after injury.
Because of LIF’s role in cardiac development, and be-
cause LIF’s collective effects counteract several processes
important in the development of ischemic cardiomyopathy,
we hypothesized that LIF may be a key signal in the process
of heart regeneration after injury. Indeed, an increase in
circulating LIF has recently been shown to induce neovas-
cularization, increase the number of cardiomyocytes in the
cell cycle, and enhance the mobilization of bone marrow
cells to the heart after MI.20 This study was undertaken to
determine whether LIF overexpression in the myocardium
bordering a large MI would block the subsequent develop-
ment of heart failure.
Methods
Animal Care
This study was conducted according to University of Pennsylvania
Institutional Animal Care and Use Committee guidelines. All
animals received humane care in compliance with the “Guide for
the Care and Use of Laboratory Animals” (http://www.nap.edu/
catalog/5140.html).
The Journal of ThoraciAdenoviral Vector Construction
Recombinant replication-deficient (E1, E3 deleted) adenoviruses
containing either the mouse LIF transgene (Adeno.LIF) or the
-galactosidase reporter gene (Adeno.LacZ), both driven by the
cytomegalovirus promoter, were produced in 293 cells and purified
as previously described.21 Empty replication-deficient adenovirus
containing no transgene as a control (Adeno.Null) was obtained
from the University of Iowa Gene Transfer Vector core (supported
in part by the National Institutes of Health and the Roy J. Carver
Foundation).
MI and Adenoviral Delivery
Thirty-five male Lewis inbred rats (250-300 g, Charles River
Laboratories, Inc, Wilmington, Mass) were anesthetized with in-
traperitoneal injections of ketamine (50 mg/kg) and xylazine (5
mg/kg), intubated, and mechanically ventilated with 0.5% isoflu-
rane. A left thoracotomy was performed, and the proximal left
anterior descending coronary artery was encircled with a 7-0
polypropylene suture. Animals were then randomly assigned in a
blinded fashion to one of three experimental groups: control, LIF,
or sham. The suture was tied to cause a large anterior MI in the
control and LIF groups, after which a total of 5  109 plaque-
forming units of either Adeno.LIF (LIF group, n  12) or Ad-
eno.Null (control group, n  12) diluted with saline solution to a
total volume of 250 L was directly injected into five areas of
myocardium bordering the ischemic area. In the sham group (n 
11), the suture was removed without being tied. All animals had
the incisions closed in three layers. Efficacy of viral delivery was
confirmed in an additional animal by injection of Adeno.LacZ
according to the described method. This rat was killed after 1
week, and X-gal staining on the heart was performed.
Confirmation of In Vivo LIF Transgene Expression
With Western Blotting
LIF viral transgene expression was confirmed in vivo with West-
ern blotting in an additional 6 animals. These animals underwent
a left thoracotomy with direct intramyocardial injections of either
Adeno.LIF (n 4) or Adeno.Null (n 2) after being anesthetized,
intubated, and ventilated as previously described. The animals had
their incisions closed and were allowed to recover, and myocardial
biopsy specimens were snap frozen in liquid nitrogen after they
were killed 1 week later. The frozen biopsy samples were pulver-
ized, homogenized in 10 volumes of sodium dodecylsulfate lysis
buffer (100-mmol/L tris[hydroxymethyl]aminomethane, pH 8.0,
10% sodium dodecylsulfate, 10-mmol/L ethylenediaminetetraace-
tic acid, 50 mmol/L dithiothreitol), and sheared with a 25-gauge
needle. After specimens were normalized for total protein content,
50 g of each sample were electrophoresed on a 12.5% sodium
dodecylsulfate–polyacrylamide gel after addition of 6 sample
loading buffer and 10 minutes of denaturation at 100°C. Proteins
were transferred to Immobilon-P (Millipore Corporation, Bedford,
Mass) with a wet transfer apparatus, and immunoblotting was
performed with a goat anti–mouse LIF antibody (R&D Systems,
Minneapolis, Minn). The actin band was identified after staining
the Immobilon-P membrane with Coomassie blue to confirm equal
loading conditions.
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Six weeks after the initial surgery, animals in the two infarct
groups and the sham group were again anesthetized, intubated,
and mechanically ventilated. A median sternotomy was per-
formed, and a 2F pressure-volume conductance catheter (Millar
Instruments, Inc, Houston, Tex) was inserted into the LV
through the apex of the heart. Baseline steady-state pressure-
volume loops were recorded for each animal. Loops were then
recorded while occluding the inferior vena cava (IVC) to reduce
preload and allow analysis of load-insensitive measures of
ventricular function. IVC occlusion measurements were re-
peated three to four times for each animal to ensure that
pressure-volume loops adequate for subsequent analysis were
obtained. Ventilations were held during all recordings to min-
imize the effects of respiratory variation.
Data was analyzed with ARIA 1 Pressure Volume Analysis
software (Millar Instruments). The following parameters were
chosen for analysis: maximum LV pressure, ejection fraction,
maximum change in pressure over time (max dP/dt), and the
max dP/dt– end-diastolic volume (EDV) relationship as systolic
function indices; minimum change in pressure over time (min
dP/dt) and the time constant of relaxation () as diastolic
function indices; and preload recruitable stroke work (PRSW)
as an index of contractility. PRSW, the slope of the relationship
between LV stroke work (SW) and EDV as calculated by linear
regression, was chosen to evaluate contractility because it al-
lows measurement of intrinsic ventricular performance inde-
pendent of loading, geometry, and heart rate and is highly linear
in the intact heart.22 PRSW was chosen rather than another
commonly used contractility measurement, the end-systolic
pressure-volume relationship, which is less linear and more
dependent on afterload conditions than PRSW and is also
highly variable in an intact cardiovascular system, probably
because of sympathetic reflexes of the autonomic system.23,24
Loops that had the linear regression coefficient for PRSW
closest to 1 were chosen for analysis among those recorded.
A cuvette calibration method was used to convert the conduc-
tance voltage waveform into volume units. Conductance values for
volumes at the low and high ends of the range for rat heart volume
were obtained by submerging the conductance catheter into two
cylindric nonconductive cuvettes of known diameter filled with
heparin-treated rat blood. Subsequent conductance measurements
were converted to volumes with a two-point linear interpolation
process. Parallel conductance from surrounding structures was
calculated by intravenous injection of a small bolus of hypertonic
saline solution and subtracted from the measured volume. Vol-
umes measured with this catheter in rat hearts correlate with
measurements made with Doppler echocardiography.25
After data collection, the heart was arrested in diastole by
injection of 0.1 mL potassium chloride (1 mEq/mL), and the LV
cavity was filled with Optimal Cutting Temperature embedding
compound fixative (Sakura Finetek USA Inc, Torrance, Calif)
retrogradely through the transected aortic root. The distended heart
was placed in a container of Optimal Cutting Temperature embed-
ding compound fixative and frozen. Sections 10 m thick were
prepared with a cryostat through the infarct region from the point
of ligation to the apex at 0.25-cm intervals.
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Measurements
Frozen sections from the middle of the infarct region were stained
with hematoxylin and eosin and evaluated with light microscopy to
assess the histologic effects of LIF overexpression. Sections were
also stained with Masson trichrome (Accustain Trichrome Stain
[Masson]; Sigma Diagnostics, St Louis, Mo) to distinguish areas
of connective tissue. Infarct size in each heart was calculated by
averaging the percentages of both inner and outer infarct scar
circumferences relative to the LV free wall on two separate sec-
tions for each heart with digitized photomicrographs and Openlab
image processing software (Improvision, Lexington, Mass). Four
measurements of LV free wall thickness in myocardium remote
from the infarct were performed on two separate sections as
previously described elsewhere.3,4
Terminal Deoxynucleotidal Transferase–Mediated
Deoxyuridine Triphosphate Nick-End Labeling Assay
The terminal deoxynucleotidal transferase–mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) assay was performed on
frozen heart sections with a TdT-FragEL DNA Fragmentation
Detection Kit (Oncogene Research Products, Boston, Mass) ac-
cording to the manufacturer’s protocol. Counterstaining with
methyl green was performed to visualize normal nuclei. The per-
centages of apoptotic nuclei per total number of nuclei from 10
separate border zone areas on two sections for each heart were
averaged.
Cardiomyocyte Size and LIF Immunohistochemical
Staining
Separate frozen sections were fixed with formaldehyde, blocked with
5% bovine serum albumin in phosphate-buffered saline solution, and
incubated either with a mouse antilaminin primary antibody (dilution
1:200 in 5% bovine serum albumin; NeoMarkers, Fremont, Calif)
followed by a rhodamine-conjugated goat antimouse secondary anti-
body (1:200; Jackson ImmunoResearch Laboratories, West Grove,
Pa) or with a goat anti–mouse LIF antibody (1:200; R&D Systems)
followed by a fluorescein-conjugated donkey antigoat secondary
antibody (1:200; Jackson ImmunoResearch Laboratories). Sec-
tions were mounted with Vectashield mounting medium with
4=-6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Bur-
lingame, Calif), which nonspecifically stains DNA to show cell
nuclei. Cardiomyocytes in cross-sectional orientation on laminin-
stained sections were analyzed with Openlab imaging software
(Improvision). Cross-sectional areas of only those cardiomyocytes
in which the nucleus was centrally located within the cell were
measured. A total of 10 fields from four border zone sections for
each heart were analyzed. Approximately 40 cells were measured
per heart. The cross-sectional areas of cardiomyocytes in myocar-
dium remote from the infarct scar were also measured in a total of
10 fields on two separate sections for each heart.
Statistical Analysis
A single, blinded investigator performed all analyses. Funding
agencies had no role in data interpretation. All values are ex-
pressed as mean  SEM. Means of two groups were compared
with the unpaired Student t test with a 2-tailed distribution. Com-
mber 2004
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PFigure 1. Viral transgene expression after direct intramyocardial injection. a, Rat heart with X-gal staining 1 week
after direct injection of Adeno.LacZ. Expression, stained blue, is seen in most cardiomyocytes in LV area of
injection. b, Immunoblotting for LIF (43 kd) transgene expression performed 1 week after virus injection shows
moderate increase in LIF expression in animals injected with Adeno.LIF (lanes 3, 4, 5, and 6) versus control animals
(lanes 1 and 2). Staining of the actin band shows equivalent protein loading in all 6 lanes. c, Merged images of
double staining of sections for LIF (green) and nonspecific nuclear stain DAPI (blue) demonstrate scattered areas
of LIF expression in myocardium bordering infarct in LIF group (left) 6 weeks after MI and viral delivery, whereas
control animals (right) do not contain areas of LIF expression (400 magnification).Figure 2. a, Hematoxylin and eosin staining demonstrates more preserved myocardium in both border zone and
infarct in LIF group than in control group (100 magnification). Control animals have more connective tissue and
fewer cardiomyocytes in border zone than LIF group animals (black arrow). LIF group animals have increased
cellularity in infarct relative to control animals (black arrowhead). b, Representative cross-sections with Masson
trichrome staining (100 magnification) of single rat heart 6 weeks after initial surgery from control group and from
LIF group show qualitatively less fibrosis with LIF. Fibrotic areas are stained blue.
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of variance followed by Tukey-Kramer post hoc testing. All sta-
tistical analyses were performed with GraphPad InStat (GraphPad
Software, Inc, San Diego, Calif).
Results
Animal Mortality
Five of the 35 animals in the main study group died in the
immediate postoperative period; 2 had received Adeno-
.LIF, 2 had received Adeno.Null, and 1 had undergone
sham operation. Animals that died had their chests im-
mediately reopened, and none had an obvious cause of
death. Deaths were presumed to be from a malignant
arrhythmia or acute respiratory insufficiency related to
the thoracotomy and heart manipulation. All animals that
survived the perioperative period lived until the time of
hemodynamic measurements. Hemodynamics could not
be measured in 1 animal in the LIF group because of
significant bleeding after sternotomy during the second
operation. This animal’s heart, however, was procured
and used for tissue analysis.
Adenoviral Delivery and Transgene Expression
X-gal staining of the animal that received Adeno.LacZ
confirmed that the viral delivery method resulted in signif-
icant cardiomyocyte transgene transfection (Figure 1, a).
Western blotting for LIF transgene expression levels in LV
myocardial biopsy samples 1 week after injection showed
increased levels of LIF expression in the LIF relative to the
control group (Figure 1, b). LIF immunofluorescent staining
6 weeks after MI and viral delivery, a time when adenoviral
transgene expression is probably significantly less than
maximum, showed that LIF group animals had scattered
areas of LIF expression in the myocardium bordering the
TABLE 1. Hemodynamics and contractility of rats injected
Sham (n
Heart rate (beats/min) 196
Maximum pressure (mm Hg) 91
EDV (L) 200 
Ejection fraction (%) 29
Max dP/dt (mm Hg/s) 4530
Min dP/dt (mm Hg/s) 4650
 (ms) 15.8
PRSW (mm Hg) 64
PRSW volume intercept (L) 88
Slope max dP/dt–EDV (mm Hg/[s · L]) 61
Max dP/dt-EDV volume intercept (L) 112
All values are mean  SEM.
*P  .05 versus sham.
†P  .05 versus control.infarct (Figure 1, c).
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Infarct size was not significantly different between the two MI
groups (LIF 42%  2% vs control 40%  3% of LV free
wall). Histologic analysis showed more preserved myocardium
in both the infarct and border zone in the LIF group than in the
control group (Figure 2, a). Masson trichrome staining quali-
tatively revealed reduced collagen deposition in the infarct in
the LIF group (Figure 2, b). Animals in the LIF group had
significantly fewer apoptotic nuclei in the border zone myo-
cardium (1.6%  0.1% vs 3.3%  0.2%, P  .05; Figure 3).
Cardiomyocytes in the border zone myocardium of the LIF
group animals had significantly greater cross-sectional areas
than border zone cardiomyocytes of the control animals (910
 60 m2 vs 480  30 m2, P  .001; Figure 4). LIF group
border zone cardiomyocytes also had increased cross-sectional
areas relative to cardiomyocytes in myocardium remote from
the infarct in both LIF group animals (910  60 m2 vs 460
 10 m2, P  .001) and control animals (910  60 m2 vs
430  30 m2, P  .001).
Cardiac Geometry and Function
Control animals had significantly decreased cardiac func-
tion relative to the sham group (Table 1). Compared with
control animals, those in the LIF group had significantly
preserved cardiac contractility and hemodynamics (Table
1 and Figures 5 and 6). Pressure-volume loops obtained
during IVC occlusion were shifted downward (decrease
in LV end-systolic pressure) and rightward (increase in
LV EDV) for the control group compared with the sham
group, whereas the LIF group had much less downward
and rightward shifting than the control group (Figure 5,
a). Animals in the LIF group had significantly preserved
systolic function, as measured by max dP/dt (Table 1 and
Figure 5, b) and the max dP/dt–EDV relationship, which
h LIF versus sham and control groups
) Control (n  10) LIF (n  10)
204 5 202 17
74 4* 85 3
301 16* 237 22†
19 2* 30 5
2750 230* 3950 360*†
2290 240* 3400 350*
20.4 1.5* 17.2 1.1
44 4* 89 10†
260 11* 181 26*†
46 6* 68 5†
216 10* 155 18†wit
 10
9
4
5
3
360
400
1.0
15
17
4
10was determined from pressure-volume loops obtained
mber 2004
c, LIF group animals had smaller percentage of TUNEL-positive cells in infarct border zone area than control animals.
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PFigure 4. Merged images of double staining of sections for laminin (red) and nonspecific nuclear stain DAPI (blue)
demonstrate significantly smaller cardiomyocytes in border zone of control group (a) than LIF group (b) (400
magnification). c, Border zone cardiomyocytes in LIF group animals had higher average cross-sectional areas than
border zone cardiomyocytes in control animals, as well as cardiomyocytes in myocardium remote from the infarctFigure 3. Representative TUNEL-stained cross-sections from single animal in control group (a) and LIF group (b)
(400 magnification). Apoptotic nuclei are stained dark brown (arrows), and normal nuclei are stained blue-green.in both LIF and control groups. *P < .001 versus control border zone; †P < .001 versus LIF remote.
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relationship, the LIF group had an increased slope and a
decreased volume intercept relative to the control group,
resulting in less rightward shift (Figure 6, a and b).
Analysis of the SW-EDV relationship, which was also
determined from pressure-volume loops obtained during
IVC occlusion, demonstrated that the LIF group had
improved cardiac contractility (Figure 6, c and d). The
LIF group had an increase in the slope of this relation-
ship, which is PRSW, as well as a decreased volume
intercept compared with controls, again resulting in less
rightward shift. For the diastolic indices of function min
dP/dt and , the LIF group animals had a trend toward
improvement relative to control animals (Table 1); how-
ever, this difference did not reach statistical significance.
LIF group animals also had greater preservation of LV
geometry than control animals. LIF reduced the amount
of LV dilation after MI, as assessed by in vivo measure-
ments of LV EDV from the conductance catheter (Table
1, Figure 5, c). LIF also attenuated the amount of LV free
wall thinning in myocardium remote from the infarct (2.1
 0.1 vs 1.8  0.1 mm, P  .05, Figure 5, d).
Discussion
CHF occurs most commonly as a result of post-MI re-
Figure 5. a, Representative pressure-volume loops for
than control relative to sham. b, LIF group had improve
control group. c, LIF group had less ventricular dila
attenuated amount of LV wall thinning in myocardium r
sham; †P < .05 versus control.modeling.1-4 Recent studies suggest that the heart has
872 The Journal of Thoracic and Cardiovascular Surgery ● Decesome innate repair mechanism, although the signaling
mechanism is unknown.9,10 LIF is a cytokine that regu-
lates the differentiation and growth of cardiac tissue and
may also regulate cardiac repair.12-20 In this study, myo-
cardial overexpression of LIF in a rat model of ischemic
cardiomyopathy provided multiple benefits. At the cellu-
lar level, LIF overexpression resulted in less infarct fi-
brosis, as well as cardiomyocyte hypertrophy and less
cell loss from apoptosis in the myocardium bordering the
infarct. This preservation of heart muscle resulted in less
ventricular wall thinning and chamber dilation after MI,
as well as preservation of cardiac systolic function and
contractility as measured in vivo by multiple parameters
with a pressure-volume conductance catheter. Overall,
LIF attenuated the development of heart failure after MI.
Interestingly, LIF expression in the heart is increased in
human patients with heart failure.26 LIF signaling is through
glycoprotein 130 receptor activation of two signal transduc-
tion intermediate families: the Janus kinase and signal trans-
ducers and the activators of transcription and mitogen-
activated protein kinase groups.16,27 LIF’s effects oppose
those of mechanical stretch and angiotensin II, which are
important in the development of heart failure. The hyper-
trophy and antiapoptotic phenotypes induced by LIF are
blocked by suppressor of cytokine signaling 3, a mechanical
, control, and LIF groups. Loops for LIF are shifted less
stolic function, as measured by max dP/dt, relative to
as measured by LV EDV, than control group. d, LIF
e from infarct relative to control group. *P< .05 versussham
d sy
tion,
emotstress–inducible cardiomyocyte gene that inhibits Janus ki-
mber 2004
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Pnase.28 Angiotensin II inhibits LIF-mediated cytoprotective
effects.29 Although LIF is already upregulated in some
forms of CHF, this study suggests that increased expression
in the myocardium bordering the infarct may be more
helpful, especially considering that the increased mechani-
cal stretch and angiotensin II levels that accompany heart
failure probably inhibit LIF’s beneficial effects. Targeting
LIF expression to the border zone may also prevent any
diastolic dysfunction that could result from inducing hyper-
trophy and blocking apoptosis throughout the heart.
This study does have limitations. First, the source of
preserved myocardium was not directly investigated and
could have been from bone marrow cell recruitment, pro-
liferation of existing cardiomyocytes, or blocked apoptosis
of border zone cardiomyocytes. Although in a recent study
LIF appeared to enhance mobilization of bone marrow cells
to the heart, another recent study showed that blocking the
Figure 6. a, LIF group shows increased slope and decr
relative to control group, indicating improved systolic f
single animal in each experimental group show LIF gro
relative to sham group. Each line on graph represents d
pressure-volume loops obtained during reduction of pr
experimental group. c, LIF group shows increase in s
decreased volume intercept relative to control group, in
relationships for single animal in each experimental g
than control group relative to sham group. Each line o
from individual pressure-volume loops obtained durin
animal from each experimental group. *P < .05 versuapoptosis of transplanted bone marrow cells significantly
The Journal of Thoracienhanced their effect of regenerating myocardium.6,20 LIF
may not increase cardiac recruitment of bone marrow cells,
but rather may prevent their death once they reach the heart.
This issue should be evaluated in a future study. Another
limitation is that adenovirus use allowed effective short-
term gene transfer, but significant expression is unlikely to
persist beyond 4 weeks. Whether the effects of short-term LIF
overexpression are transient or permanent was not determined.
Longer term studies are needed to see whether short-term
overexpression permanently blocks or simply delays the onset
of heart failure. Finally, virally mediated gene transfer may not
provide optimal clinical applicability. LIF may have some
potential for ultimate systemic use because it works on cell
membrane receptors. This study’s results may more impor-
tantly help further knowledge into the molecular mechanisms
of the postinfarction remodeling process.
MI leads to myocardial necrosis and apoptosis and ulti-
d volume intercept for max dP/dt and EDV relationship
on. b, Representative max dP/dt–EDV relationships for
ifted rightward and downward less than control group
oints for max dP/dt and EDV measured from individual
volume by IVC occlusion for single animal from each
of SW-EDV relationship, which is PRSW, as well as
ting increased contractility. d, Representative SW-EDV
show LIF group shifted rightward and downward less
ph represents data points for SW and EDV measured
uction of preload volume by IVC occlusion for single
m; †P < .05 versus control.ease
uncti
up sh
ata p
eload
lope
dica
roup
n gra
g redmately to heart failure. LIF is a cytokine that regulates heart
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CSPtissue by inducing cardiomyocyte proliferation and hyper-
trophy, blocking apoptosis, modulating cardiac fibroblast
activity, and mobilizing bone marrow cells to the heart. Our
results show that LIF gene transfer preserves both myocar-
dium and cardiac function after MI.
We are grateful to Dr. Bradley Kerr for his assistance in
providing the LIF adenovirus. We also acknowledge the McGrath
Foundation’s support of Dr Patterson’s laboratory.
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Discussion
Dr Mark Ratcliffe (San Francisco, Calif). Do you have any idea
what the blood flow in the border zone is doing in these animals?
One of the really interesting things that came out of Gorman’s
work at Penn was in sheep where the border zone was seen to be
normally perfused. The sheep doesn’t have any preformed intra-
arterial collaterals, and I am not sure whether the rat does. But that
border zone went on to remodel, presumably because of the
phenomenon that was discussed in an earlier presentation, specif-
ically abnormal strain and stress patterns. Do you think that is what
is happening here? Do you have any information about blood
flow?
Dr Berry. We did not measure any blood flow parameter in this
study, either by counting capillaries or using microcrystals to
quantify blood flow. We have found in other studies with this
model that the use of angiogenic agents resulted in an improve-
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Pment in function, suggesting that increased vascularization of the
border zone will alter the remodeling process.
Dr Ross M. Ungerleider (Portland, Ore). I am curious about
one thing related to your model, and this is probably because I
haven’t worked with a rat model, but if you ligate the left anterior
descending coronary artery and the animals survive, then how
appropriate a model is that? I would imagine that that would be a
fairly serious ischemic injury. So maybe there is a lot of collater-
alization or something that allows these animals to survive, and I
am just wondering how applicable that is to more human situa-
tions.
Dr Berry. Where the artery is ligated does determine the
survival of the animals. We have found that ligating too high on
the left anterior descending coronary artery, around the level of the
pulmonary artery, results in a mortality as high as 50%. We try to
ligate in the same point in the middle of the left anterior descend-
ing coronary artery in all animals, and we now have about a 15%
mortality overall, which we find to be acceptable in terms of both
our animals and our experimental reagents.
In terms of clinical applicability, we were most interested in
studying LIF’s effects as the ventricle changes by comparing them
to what happens if you don’t do anything to the border zone area.
In this study, adenovirus, which we don’t really see much clinical
utility for in the long term, was used for proof of principle.
One of the things that excites us about LIF is that it is an
extracellular protein that doesn’t need to get inside the cell to exert
its effects. LIF as a pharmacologic agent therefore might be able to
ultimately provide benefit, at least if it does prove to have benefit
in larger animals and eventually in humans.
Dr Robert C. Robbins (Stanford, Calif). You injected this
right at the time you created the infarct. Clinically, we are really
not going to be there at the time. Potentially you could do this in
the catheter lab, and that might have some utility to preserve
myocardial function, but surgically long term, have you done any
studies where you ligated the LAD and then came back, say, a
month later?
Dr Berry. No, we haven’t performed those types of studies.
However, one advantage in this case of using adenovirus is that
you don’t really start getting expression for a couple of days. So
The Journal of Thoracieven though we delivered the vector at the time of the MI, we
would expect the treatment really to start a few days later and
probably only last for a couple of weeks.
Dr Michael Mann (San Francisco, Calif). I have two some-
what mechanism-related questions. First, the control animals that
had ischemia all apparently were treated with a control adenovirus,
which itself can cause inflammation and may have a deleterious
effect downstream on ventricular recovery. I am wondering
whether you ever compared your treated hearts with vehicle or
non–adenovirus infected hearts?
Second, LIF, as you know, acts through upregulated expression
of a number of target genes. Did you look for upregulated expres-
sion of any of those key targets in the hearts that you did treat?
Dr Berry. To answer the first question, we didn’t do any
experiments in which we just injected vehicle; we used only the
Adeno.Null virus as a control. We have done studies not involving
adenovirus with this model, though, in which the control animals
have just received injections of saline or phosphate-buffered saline
solution, and we find that the function in those control groups is
pretty much equivalent to the function that we see in the animals
that get the null virus. We did have concerns initially that the
Adeno.Null virus might actually be causing negative effects that
would cause us to overestimate the effects of our treatment, but
now we don’t think that that is the case in our model.
We haven’t looked at other intracellular markers, and that is
something that we want to follow up on in response to these
results.
Dr Robbins. I have a technical question about your assessment
of apoptosis. I am assuming it was consistently done in the border
zone for both groups, but can you comment on the use of just
TUNEL to differentiate between apoptosis and necrosis, which has
been a big criticism? We have used in situ oligo ligation TUNEL
and other caspase analysis of apoptosis, and you just use TUNEL.
Dr Berry. We have found previously in our lab with some
other techniques that the TUNEL assay gave pretty equivalent
measurements of apoptosis. We also have heard that criticism of
TUNEL, and we are trying to develop some caspase assays to
corroborate the TUNEL results.
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